Previous close | 6.00 |
Open | 6.00 |
Bid | 0.95 |
Ask | 10.00 |
Strike | 400.00 |
Expiry date | 2024-06-21 |
Day's range | 6.00 - 6.00 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Company Faces Decline in Life Sciences but Gains in Clinical Diagnostics
Bio-Rad (BIO) delivered earnings and revenue surprises of 12.25% and 0.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
HERCULES, Calif., May 07, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2024.